These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

135 related items for PubMed ID: 8343260

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Adjuvant treatment in stage I and II malignant melanoma: a randomized trial between chemoimmunotherapy and immunotherapy.
    Castel T, Estapé J, Viñolas N, Mascaró JM, Castro J, Vilalta A, Gratacós R, Daniels M, Palou J, Grau JJ.
    Dermatologica; 1991; 183(1):25-30. PubMed ID: 1769411
    [Abstract] [Full Text] [Related]

  • 5. Adjuvant reactivity predicts survival in patients with "high-risk" primary malignant melanoma treated with systemic BCG. EORTC Malignant Melanoma Cooperative Group Writing Committee.
    Cochran AJ, Buyse ME, Lejeune FJ, Macher E, Revuz J, Rümke P.
    Int J Cancer; 1981 Nov 15; 28(5):543-50. PubMed ID: 7309294
    [Abstract] [Full Text] [Related]

  • 6. Long-Term Survival after Complete Surgical Resection and Adjuvant Immunotherapy for Distant Melanoma Metastases.
    Faries MB, Mozzillo N, Kashani-Sabet M, Thompson JF, Kelley MC, DeConti RC, Lee JE, Huth JF, Wagner J, Dalgleish A, Pertschuk D, Nardo C, Stern S, Elashoff R, Gammon G, Morton DL, MMAIT-IV Clinical Trial Group.
    Ann Surg Oncol; 2017 Dec 15; 24(13):3991-4000. PubMed ID: 29019177
    [Abstract] [Full Text] [Related]

  • 7. Corynebacterium parvum versus bacille Calmette-Guérin adjuvant immunotherapy of stage II malignant melanoma.
    Lipton A, Harvey HA, Balch CM, Antle CE, Heckard R, Bartolucci AA.
    J Clin Oncol; 1991 Jul 15; 9(7):1151-6. PubMed ID: 2045856
    [Abstract] [Full Text] [Related]

  • 8. Adjuvant immunotherapy with BCG in stage II malignant melanoma.
    Byrne MJ, Van Hazel G, Reynolds PM, Lemish WM, Holman CD.
    J Surg Oncol; 1983 Jun 15; 23(2):114-6. PubMed ID: 6343725
    [Abstract] [Full Text] [Related]

  • 9. Preliminary results of a randomized trial of adjuvant immunotherapy in patients with malignant melanoma who have lymph node metastases.
    Morton DL, Eilber FR, Holmes EC, Ramming KP.
    Aust N Z J Surg; 1978 Feb 15; 48(1):49-52. PubMed ID: 276348
    [Abstract] [Full Text] [Related]

  • 10. Corynebacterium parvum versus BCG adjuvant immunotherapy in human malignant melanoma.
    Lipton A, Harvey HA, Lawrence B, Gottlieb R, Kukrika M, Dixon R, Graham W, Miller S, Heckard R, Schelzel D, White DS.
    Cancer; 1983 Jan 01; 51(1):57-60. PubMed ID: 6821809
    [Abstract] [Full Text] [Related]

  • 11. Results of adjuvant BCG immunotherapy in malignant melanoma.
    Wätzig V, Knopf B.
    Arch Geschwulstforsch; 1981 Jan 01; 51(6):493-6. PubMed ID: 7332442
    [Abstract] [Full Text] [Related]

  • 12. A clinical trial of BCG immunotherapy as an adjunct to surgery in the treatment of primary malignant melanoma.
    O'Connor TP, Labandter HP, Hiles RW, Bodenham DC.
    Br J Plast Surg; 1978 Oct 01; 31(4):317-22. PubMed ID: 361132
    [Abstract] [Full Text] [Related]

  • 13. Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): a trial of the Eastern Oncology Group.
    Agarwala SS, Neuberg D, Park Y, Kirkwood JM.
    Cancer; 2004 Apr 15; 100(8):1692-8. PubMed ID: 15073858
    [Abstract] [Full Text] [Related]

  • 14. Results of a Randomised Controlled Trial Comparing Intravesical Chemohyperthermia with Mitomycin C Versus Bacillus Calmette-Guérin for Adjuvant Treatment of Patients with Intermediate- and High-risk Non-Muscle-invasive Bladder Cancer.
    Arends TJ, Nativ O, Maffezzini M, de Cobelli O, Canepa G, Verweij F, Moskovitz B, van der Heijden AG, Witjes JA.
    Eur Urol; 2016 Jun 15; 69(6):1046-52. PubMed ID: 26803476
    [Abstract] [Full Text] [Related]

  • 15. A randomized trial of adjuvant chemotherapy and immunotherapy in Stage I and Stage II cutaneous melanoma. An interim report.
    Sterchi JM, Wells HB, Case LD, Spurr CL, White DR, Richards F, Muss HB, Jackson DV, Stuart JJ, Cooper MR.
    Cancer; 1985 Feb 15; 55(4):707-12. PubMed ID: 3967167
    [Abstract] [Full Text] [Related]

  • 16. Randomized trial of adjuvant therapy for "high risk" primary malignant melanoma.
    Wood WC, Cosimi AB, Carey RW, Kaufman SD.
    Surgery; 1978 Jun 15; 83(6):677-81. PubMed ID: 644461
    [Abstract] [Full Text] [Related]

  • 17. Adjuvant therapy of melanoma.
    Agarwala SS, Kirkwood JM.
    Semin Surg Oncol; 1998 Jun 15; 14(4):302-10. PubMed ID: 9588723
    [Abstract] [Full Text] [Related]

  • 18. Surgical adjuvant therapy for malignant melanoma.
    Pinsky CM, Oettgen HF.
    Surg Clin North Am; 1981 Dec 15; 61(6):1259-66. PubMed ID: 7031933
    [No Abstract] [Full Text] [Related]

  • 19. [Immunotherapy of malignant melanoma].
    Adler A.
    Harefuah; 1986 Jul 15; 111(1-2):11-7. PubMed ID: 3781371
    [No Abstract] [Full Text] [Related]

  • 20. Improved survival in patients with poor-prognosis malignant melanoma treated with adjuvant levamisole: a phase III study by the National Cancer Institute of Canada Clinical Trials Group.
    Quirt IC, Shelley WE, Pater JL, Bodurtha AJ, McCulloch PB, McPherson TA, Paterson AH, Prentice R, Silver HK, Willan AR.
    J Clin Oncol; 1991 May 15; 9(5):729-35. PubMed ID: 2016615
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.